Irex Pharma LLC

Chapel Hill, NC · Biotech · Private

Small molecule IRE1β kinase and RNase inhibitors for reducing airway mucus overproduction in asthma

Grants
$1.2M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma$300,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma$599,999
Federal grantDepartment of Health and Human Services · Phase I · IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma$299,999
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1359FIBROSIX INC.——
1360PARAMITA THERAPEUTICS, INC.——
1361Abceutics——
1362Irex Pharma LLC——
1363CALISTA THERAPEUTICS INC——
1364DOOR PHARMACEUTICALS, LLC——
1365ADECTO PHARMACEUTICALS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.